Name | Atoltivimab |
---|
Description | Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and Drug Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection[1]. |
---|---|
Related Catalog | |
Target |
Ebolaviru (EBOV)[1] |
References |
No Any Chemical & Physical Properties |